05.22.14
InVivo Therapeutics Holdings Corp. has appointed Thomas R. Ulich, M.D., as chief scientific officer.
Ulich previously served as executive vice president of Research and Development of ConjuChem Biotechnologies from 2006 to 2010. Prior to that, he served as senior vice president of Research and Development for Alnylam Pharmaceuticals from 2003 to 2004. Before that he served at Amgen as vice president of Preclinical Development from 1993 to 2001 and as vice president of Preclinical Development and Protein Therapeutics from 2001 until 2003.
Ulich has a bachelor of arts degree from Dartmouth College in Hanover, N.H., and a medical degree from the University of California-Los Angeles Medical School. He has medical board certification from the American Board of Anatomic Pathology, the American Board of Clinical Pathology, and the American Board of Immunopathology.
“Tom Ulich brings to InVivo a broad scientific background and expertise that will be invaluable as we build our biomaterials portfolio,” InVivo CEO Mark Perrin said.
InVivo Therapeutics Holdings Corp. focuses on polymer-based platform technology to develop treatments for traumatic spine and brain injuries. The company is based in Cambridge, Mass.
Ulich previously served as executive vice president of Research and Development of ConjuChem Biotechnologies from 2006 to 2010. Prior to that, he served as senior vice president of Research and Development for Alnylam Pharmaceuticals from 2003 to 2004. Before that he served at Amgen as vice president of Preclinical Development from 1993 to 2001 and as vice president of Preclinical Development and Protein Therapeutics from 2001 until 2003.
Ulich has a bachelor of arts degree from Dartmouth College in Hanover, N.H., and a medical degree from the University of California-Los Angeles Medical School. He has medical board certification from the American Board of Anatomic Pathology, the American Board of Clinical Pathology, and the American Board of Immunopathology.
“Tom Ulich brings to InVivo a broad scientific background and expertise that will be invaluable as we build our biomaterials portfolio,” InVivo CEO Mark Perrin said.
InVivo Therapeutics Holdings Corp. focuses on polymer-based platform technology to develop treatments for traumatic spine and brain injuries. The company is based in Cambridge, Mass.
InVivo Therapeutics Holdings Corp. focuses on polymer-based platform technology to develop treatments for traumatic spine and brain injury. The company is based in Cambridge, Mass. - See more at: http://dev.mpo-mag.com/contents/view_breaking-news/2013-09-17/invivo-hires-interim-cfo#sthash.OFlRtWGP.dpuf